Table 1 The demographic data of GR, PR, and Placebo group
Placebo (n = 12) | GR (n = 10) | PR (n = 12) | p-value Placebo vs. GR | p-value Placebo vs. PR | p-value GR vs. PR | |
|---|---|---|---|---|---|---|
Age | 61.8 ± 5.01 | 65.8 ± 7.11 | 65.1 ± 6.72 | 0.429 | 0.613 | > 0.999 |
Sex(Female) | 6 (50.0%) | 9 (90.0%) | 8 (66.7%) | 0.074 | 0.680 | 0.323 |
APOE ε4 carrier | 7 (58.3%) | 8 (80.0%) | 5/11 (45.5%)† | 0.381 | 0.684 | 0.183 |
Baseline amyloid beta(pg/mL), mean ± SD | 202.47 ± 112.38 | 431.53 ± 153.55 | 242.68 ± 132.93 | 0.001* | > 0.999 | 0.007* |
Baseline T-Tau(pg/mL), mean ± SD | 344.80 ± 200.80 | 614.99 ± 139.08 | 322.06 ± 140.61 | 0.002* | > 0.999 | < 0.001* |
Baseline P-tau(pg/mL), mean ± SD | 39.94 ± 23.02 | 67.10 ± 13.90 | 40.63 ± 25.05 | 0.019* | > 0.999 | 0.023* |
ADAS-Cog, mean ± SD | 20.3 ± 4.44 | 18.6 ± 4.77 | 24.1 ± 5.98 | > 0.999 | 0.248 | 0.054 |
MMSE, mean ± SD | 22.5 ± 4.12 | 23.9 ± 3.81 | 20.4 ± 4.36 | > 0.999 | 0.675 | 0.172 |
Florbetaben PET positive | 12 (100%) | 10 (100%) | 12 (100%) | > 0.999 | > 0.999 | > 0.999 |